SCHEMBL30298601

SCHEMBL30298601

O=C(CBr)c1ccc(Cn2cccn2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.65
HDAC6 Q9UBN7 1/20 0.65
HTT P42858 1/20 0.54
MAPT P10636 3/20 0.50
GAA P10253 2/20 0.50
NOS3 P29474 1/20 0.49
NOS1 P29475 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
PTPN1 P18031 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24663640 0.86 HDAC1 (0.67) HDAC1HDAC6HTTMAPTGAA
SCHEMBL17303471 0.84 HDAC1 (0.72) HDAC1HDAC6HTTMAPTGAA
SCHEMBL3584847 0.83 HDAC1 (0.70) HDAC1HDAC6HTTMAPTGAA
SCHEMBL27273122 0.83 HDAC1 (0.70) HDAC1HDAC6HTTMAPTGAA
SCHEMBL17221212 0.81 HDAC1 (0.68) HDAC1HDAC6HTTMAPTGAA
SCHEMBL4915929 0.81 HDAC1 (0.68) HDAC1HDAC6HTTMAPTGAA
SCHEMBL29277938 0.81 HDAC1 (0.60) HDAC1HDAC6HTTMAPTGAA
SCHEMBL12472822 0.79 HDAC1 (1.00) HDAC1HDAC6HTTMAPTGAA
SCHEMBL16246919 0.79 MAPT (0.60) HDAC1HDAC6HTTMAPTGAA
SCHEMBL29278007 0.78 HDAC1 (0.60) HDAC1HDAC6HTTMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139286-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 EP disclosed
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-04-23 US disclosed
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230139936-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139936-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG HDAC1 2796/4885HDAC6 3142/4885HTT 3914/4885
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG HDAC1 2796/4885HDAC6 3142/4885HTT 3914/4885
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation DGKZ, DGKA, DGKG HDAC1 2796/4885HDAC6 3142/4885HTT 3914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.